Publication
Title
Renin-angiotensin system inhibitors to mitigate cancer treatment-related adverse events
Author
Abstract
Treatment-related side effects are a major clinical problem in cancer treatment. They lead to reduced compliance to therapy as well as increased morbidity and mortality. Wellknown are the sequelae of chemotherapy on the heart, especially in childhood cancer survivors. Therefore, measures to mitigate the adverse events of cancer therapy may improve health and quality of life in patients with cancer, both in the short and long term. The renin-angiotensin system (RAS) affects all hallmarks of cancer, and blockage of the RAS is associated with an improved outcome in several cancer types. There is also increasing evidence that inhibition of the RAS might be able to alleviate or even prevent certain types of cancer treatment-related adverse effects. In this review, we summarize the potential of RAS inhibitors to mitigate cancer treatment-related adverse events, with a special emphasis on chemotherapy-induced cardiotoxicity, radiation injury, and arterial hypertension. (C) 2018 AACR.
Language
English
Source (journal)
Clinical cancer research. - Philadelphia, Pa, 1995, currens
Publication
Philadelphia : Amer assoc cancer research , 2018
ISSN
1078-0432 [print]
1557-3265 [online]
Volume/pages
24 :16 (2018) , p. 3803-3812
ISI
000441804700004
Pubmed ID
29610292
Full text (Publisher's DOI)
Full text (open access)
Full text (publisher's version - intranet only)
UAntwerpen
Faculty/Department
Research group
Publication type
Subject
Affiliation
Publications with a UAntwerp address
External links
Web of Science
Record
Identification
Creation 07.09.2018
Last edited 20.09.2021
To cite this reference